405 related articles for article (PubMed ID: 23037867)
1. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne.
Girmenia C; Aversa F; Busca A; Candoni A; Cesaro S; Luppi M; Pagano L; Rossi G; Venditti A; Nosari AM; ; ; ; ;
Hematol Oncol; 2013 Sep; 31(3):117-26. PubMed ID: 23037867
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Girmenia C; Barosi G; Piciocchi A; Arcese W; Aversa F; Bacigalupo A; Bandini G; Bosi A; Busca A; Castagnola E; Caselli D; Cesaro S; Ciceri F; Locasciulli A; Locatelli F; Mikulska M; Pagano L; Prete A; Raiola AM; Rambaldi A
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1080-8. PubMed ID: 24582783
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Girmenia C; Barosi G; Aversa F; Bacigalupo A; Barbui T; Baronciani D; Bosi A; Candoni A; Locasciulli A; Locatelli F; Menichetti F; Musso M; Viscoli C; Rambaldi A
Clin Infect Dis; 2009 Oct; 49(8):1226-36. PubMed ID: 19772390
[TBL] [Abstract][Full Text] [Related]
5. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.
Hematol Cell Ther; 1999 Jun; 41(3):117-25. PubMed ID: 10456442
[No Abstract] [Full Text] [Related]
7. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
Cornely OA; Ullmann AJ; Karthaus M
Blood; 2003 May; 101(9):3365-72. PubMed ID: 12393455
[TBL] [Abstract][Full Text] [Related]
9. Treatment of childhood acute lymphoblastic leukemia in first remission with allogeneic bone marrow transplantation or with intensive chemotherapy: a cooperative Italian study. The AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy.
Uderzo C; Valsecchi MG; Balduzzi A; Rovelli A; Dini G; Miniero R; Locatelli F; Rondelli R; Arcese W; Andolina M; Messina C; Polchi P; Biagi E; Arrigo C; Silvestri D; Masera G; Bacigalupo A
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():25-7. PubMed ID: 8932793
[No Abstract] [Full Text] [Related]
10. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
11. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
12. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
14. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
Ping B; Zhu Y; Gao Y; Yue C; Wu B
Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
[TBL] [Abstract][Full Text] [Related]
15. Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?
Dragonetti G; Criscuolo M; Fianchi L; Pagano L
Med Mycol; 2017 Jan; 55(1):82-86. PubMed ID: 27915304
[TBL] [Abstract][Full Text] [Related]
16. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
Kanda Y; Kimura SI; Iino M; Fukuda T; Sakaida E; Oyake T; Yamaguchi H; Fujiwara SI; Jo Y; Okamoto A; Fujita H; Takamatsu Y; Saburi Y; Matsumura I; Yamanouchi J; Shiratori S; Gotoh M; Nakamura S; Tamura K;
J Clin Oncol; 2020 Mar; 38(8):815-822. PubMed ID: 31977270
[TBL] [Abstract][Full Text] [Related]
17. [Current indications for voriconazole in onco-hematological patients].
Jarque I; Sanz MA
Rev Iberoam Micol; 2007 Sep; 24(3):213-6. PubMed ID: 17874858
[TBL] [Abstract][Full Text] [Related]
18. Antifungal prophylaxis in the haematological patient: a practical approach.
Vázquez L; Carreras E; Serrano D; Jarque I; Mensa J; Barberán J
Rev Esp Quimioter; 2012 Dec; 25(4):299-304. PubMed ID: 23303265
[TBL] [Abstract][Full Text] [Related]
19. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.
Chanock SJ; Walsh TJ
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S15-20. PubMed ID: 8971401
[TBL] [Abstract][Full Text] [Related]
20. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
Selvy N; Villiet M; Hansel-Esteller S
Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
